Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     

JOHNSON & JOHNSON

(JNJ)
  Report
Delayed Nyse  -  04:00 2022-09-30 pm EDT
163.36 USD   -0.71%
09/28Trending : Johnson & Johnson's New Band-Aid, Tylenol Company to Be Named Kenvue
DJ
09/28Johnson & Johnson : Vision Introduces All Purpose EDOF, TECNIS Symfony OptiBlue IOL, the Latest PC-IOL Powered by InteliLight Technology
PU
09/28Johnson & Johnson Says Planned Consumer Health Company to Be Named Kenvue
MT
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

The Janssen Pharmaceutical Companies of Johnson & Johnson Announces European Commission Approves IMBRUVICA® in a Fixed-Duration Combination Regimen for Adult Patients with Previously Untreated Chronic Lymphocytic Leukaemia

08/04/2022 | 03:00am EDT

The Janssen Pharmaceutical Companies of Johnson & Johnson announced that the European Commission granted marketing authorisation for the expanded use of IMBRUVICA® (ibrutinib) in an all-oral, fixed-duration (FD) treatment combination with venetoclax (I+V) for adults with previously untreated chronic lymphocytic leukaemia (CLL). The approval is based on the pivotal Phase 3 GLOW study that demonstrated superior progression-free survival (PFS) in patients treated with I+V versus chlorambucil-obinutuzumab (Clb+O), and the FD cohort of the Phase 2 CAPTIVATE study, which showed deep and durable responses in patients treated with I+V, including those with high-risk features. In Europe, ibrutinib is already approved as a continuous therapy in several indications across three blood cancers (CLL, mantle cell lymphoma and Waldenström's macroglobulinaemia).3 In CLL, patient outcomes have improved over the last decade.4 A wave of innovation, including the advent of novel oral therapies that target the underlying disease biology, has shifted the standard of care from chemoimmunotherapy to targeted agents and combination therapies.4 Unmet needs remain, including time-limited combinations of targeted therapies that provide durable remissions and the flexibility to better tailor first-line therapy.


© S&P Capital IQ 2022
All news about JOHNSON & JOHNSON
09/28Trending : Johnson & Johnson's New Band-Aid, Tylenol Company to Be Named Kenvue
DJ
09/28Johnson & Johnson : Vision Introduces All Purpose EDOF, TECNIS Symfony OptiBlue IOL, the L..
PU
09/28Johnson & Johnson Says Planned Consumer Health Company to Be Named Kenvue
MT
09/28Johnson & Johnson Announces Kenvue as the Name for Planned New Consumer Health Company
BU
09/28Johnson & Johnson Announces Kenvue as the Name for Planned New Consumer Health Company
CI
09/27Legend Biotech's Cancer Drug Carvykti Gets Japanese Approval to Treat Certain Adults wi..
MT
09/22US Stocks End Lower Thursday Despite Healthcare Gains
MT
09/22US Stocks End Lower Thursday Despite Surge in Healthcare Shares
MT
09/22Johnson & Johnson - Diversifying Our Health Workforce through the Impact of AIM
AQ
09/22Over 200 Inmates, Prison Officers Vaccinated Against Covid-19
AQ
More news
Analyst Recommendations on JOHNSON & JOHNSON
More recommendations
Financials (USD)
Sales 2022 95 525 M - -
Net income 2022 22 023 M - -
Net cash 2022 9 791 M - -
P/E ratio 2022 20,0x
Yield 2022 2,68%
Capitalization 430 B 430 B -
EV / Sales 2022 4,39x
EV / Sales 2023 4,11x
Nbr of Employees 141 700
Free-Float 84,2%
Chart JOHNSON & JOHNSON
Duration : Period :
Johnson & Johnson Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends JOHNSON & JOHNSON
Short TermMid-TermLong Term
TrendsNeutralBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 20
Last Close Price 163,36 $
Average target price 185,07 $
Spread / Average Target 13,3%
EPS Revisions
Managers and Directors
Joaquin Duato Chief Executive Officer & Director
Joseph J. Wolk Chief Financial Officer & Executive Vice President
Matthew Stuckley Senior Financial Analyst-Janssen Commercial Pharm
Alex Gorsky Executive Chairman
Peter Shen Global Head-Research & Development
Sector and Competitors
1st jan.Capi. (M$)
JOHNSON & JOHNSON-4.51%429 503
ELI LILLY AND COMPANY17.06%307 239
ROCHE HOLDING AG-14.68%271 055
PFIZER, INC.-25.89%245 597
ABBVIE INC.-0.88%237 296
NOVO NORDISK A/S3.59%227 057